Biologics
8
3
4
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
12.5%
1 terminated out of 8 trials
66.7%
-19.8% vs benchmark
25%
2 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (8)
Real-world Immunogenicity of Anti-IL5/5a Antibody
Efficacy of Mesalazine Combined With Biologics in the Treatment of Moderate to Severe Ulcerative Colitis
Quantify the Value of Transmural Inflammation in the Treatment of Crohn's Disease With Ustekinumab:an Analysis Based on Imaging Science
A Cohort Study of the Efficacy and Safety of Biologics in Patients With ABPA
A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)
Continuous HRV Monitoring for Predicting Response to Biologic Therapy in IBD
A Multi-center RCT Clinical Trial on Personalized Precision Medicine for Patients With Psoriasis and Psoriatic Arthritis and Investigation on Cardiovascular Biomarkers
Tofacitinib Registry of Patients With Ulcerative Colitis in Germany